Lack of exposure to pharmacogenomics education among the health care providing students in the West Bank of Palestine.
West Bank of Palestine
education
knowledge
pharmacogenomics (PGx)
Journal
Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
29
10
2022
accepted:
23
01
2023
medline:
18
9
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
epublish
Résumé
Evaluating the knowledge in pharmacogenomics (PGx) is the first step toward the implementation of PGx testing in clinical practice. This survey aimed to evaluate the knowledge of PGx testing among healthcare providing students at the top-ranked university in the West Bank of Palestine. First an online questionnaire consisting of 30 questions regarding the demographic, knowledge, and attitude toward pharmacogenomics testing was structured and validated. Then the questionnaire was distributed to 1,000 current students from different fields. 696 responses was received. The results showed that almost half of the participants (n=355, 51.1%) have never took any courses about PGx during their university training. Only 81 (11.7%) of the students who took the PGx course stated that it helped them understanding how genetic variations affect drug response. The majority of the students were uncertain (n=352, 50.6%) or disagreed (n=143, 20.6%) that the lectures during university education described the effects of genetic variants on drug response. Although most of the students (70-80%) answered that genetic variants can indeed affect the drug's response, only 162 students (23.3%) responded that It is concluded from the results of this survey that there is a lack of exposure to PGx education associated with poor knowledge of PGx testing among the healthcare providing students in the West Bank of Palestine. It is recommended to include and improve the lectures and courses regarding PGx as this will have a major impact on precision medicine.
Identifiants
pubmed: 36913309
pii: dmpt-2022-0180
doi: 10.1515/dmpt-2022-0180
doi:
Substances chimiques
VKORC1 protein, human
EC 1.17.4.4
Vitamin K Epoxide Reductases
EC 1.17.4.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-272Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Roden, DM, Wilke, RA, Kroemer, HK, Stein, CM. Pharmacogenomics: the genetics of variable drug responses. Circulation 2011;123:1661–70. https://doi.org/10.1161/circulationaha.109.914820 .
doi: 10.1161/circulationaha.109.914820
Alhawari, H, Jarrar, Y, AlKhatib, MA, Alhawari, H, Momani, M, Zayed, A, et al.. The association of 3-hydroxy-3-methylglutaryl-CoA reductase, apolipoprotein E, and solute carrier organic anion genetic variants with atorvastatin response among Jordanian patients with type 2 diabetes. Life 2020;10:232. https://doi.org/10.3390/life10100232 .
doi: 10.3390/life10100232
Malsagova, KA, Butkova, TV, Kopylov, AT, Izotov, AA, Potoldykova, NV, Enikeev, DV, et al.. Pharmacogenetic testing: a tool for personalized drug therapy optimization. Pharmaceutics 2020;12:1240. https://doi.org/10.3390/pharmaceutics12121240 .
doi: 10.3390/pharmaceutics12121240
Caldwell, MD, Awad, T, Johnson, JA, Gage, BF, Falkowski, M, Gardina, P, et al.. CYP4F2 genetic variant alters required warfarin dose. Blood 2008;111:4106–12. https://doi.org/10.1182/blood-2007-11-122010 .
doi: 10.1182/blood-2007-11-122010
Jarrar, YB, Lee, SJ. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy. Drug Metabol Drug Interact 2014;29:211–20. https://doi.org/10.1515/dmdi-2014-0001 .
doi: 10.1515/dmdi-2014-0001
Tariq, RA, Vashisht, R, Sinha, A, Scherbak, Y. Medication dispensing errors and prevention . Treasure Island (FL): StatPearls; 2022.
Scharfe, CPI, Tremmel, R, Schwab, M, Kohlbacher, O, Marks, DS. Genetic variation in human drug-related genes. Genome Med 2017;9:117. https://doi.org/10.1186/s13073-017-0502-5 .
doi: 10.1186/s13073-017-0502-5
Whirl-Carrillo, M, Huddart, R, Gong, L, Sangkuhl, K, Thorn, CF, Whaley, R, et al.. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2021;110:563–72. https://doi.org/10.1002/cpt.2350 .
doi: 10.1002/cpt.2350
Jarrar, Y, Mosleh, R, Hawash, M, Jarrar, Q. Knowledge and attitudes of pharmacy students towards pharmacogenomics among universities in Jordan and West Bank of Palestine. Pharmgenomics Pers Med 2019;12:247–55. https://doi.org/10.2147/pgpm.s222705 .
doi: 10.2147/pgpm.s222705
Murphy, JE, Green, JS, Adams, LA, Squire, RB, Kuo, GM, McKay, A. Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am J Pharmaceut Educ 2010;74:7. https://doi.org/10.5688/aj740107 .
doi: 10.5688/aj740107
Rahma, AT, Elsheik, M, Elbarazi, I, Ali, BR, Patrinos, GP, Kazim, MA, et al.. Knowledge and attitudes of medical and health science students in the United Arab Emirates toward genomic medicine and pharmacogenomics: a cross-sectional study. J Pers Med 2020;10:191. https://doi.org/10.3390/jpm10040191 .
doi: 10.3390/jpm10040191
Arafah, A, Rehman, MU, Syed, W, Babelghaith, SD, Alwhaibi, A, Al Arifi, MN. Knowledge, attitude and perception of pharmacy students towards pharmacogenomics and genetics: an observational study from King Saud University. Genes 2022;13:269. https://doi.org/10.3390/genes13020269 .
doi: 10.3390/genes13020269
Daniel, WW. Biostatistics, a foundation for analysis in the health sciences , 4th ed. New York: Wiley; 1987, vol xiii:733 p.
Tavakol, M, Dennick, R. Making sense of Cronbach’s alpha. Int J Med Educ 2011;2:53–5. https://doi.org/10.5116/ijme.4dfb.8dfd .
doi: 10.5116/ijme.4dfb.8dfd
Turner, RM, Park, BK, Pirmohamed, M. Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med 2015;7:221–41. https://doi.org/10.1002/wsbm.1302 .
doi: 10.1002/wsbm.1302
Aneesh, T, Sekhar, S, Jose, A, Chandran, L, Zachariah, SM. Pharmacogenomics: the right drug to the right person. J Clin Med Res 2009;1:191–4. https://doi.org/10.4021/jocmr2009.08.1255 .
doi: 10.4021/jocmr2009.08.1255
Bishop, JR, Huang, RS, Brown, JT, Mroz, P, Johnson, SG, Allen, JD, et al.. Pharmacogenomics education, research and clinical implementation in the state of Minnesota. Pharmacogenomics 2021;22:681–91. https://doi.org/10.2217/pgs-2021-0058 .
doi: 10.2217/pgs-2021-0058
Hippman, C, Nislow, C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med 2019;9:40. https://doi.org/10.3390/jpm9030040 .
doi: 10.3390/jpm9030040
Wang, B, Canestaro, WJ, Choudhry, NK. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. JAMA Intern Med 2014;174:1938–44. https://doi.org/10.1001/jamainternmed.2014.5266 .
doi: 10.1001/jamainternmed.2014.5266
Tata, E, Ambele, M, Pepper, M. Barriers to implementing clinical pharmacogenetics testing in sub-Saharan Africa. A critical review. Pharmaceutics 2020;12:809. https://doi.org/10.3390/pharmaceutics12090809 .
doi: 10.3390/pharmaceutics12090809
Jarrar, Y, Musleh, R, Ghanim, M, AbuKhader, I, Jarrar, Q. Assessment of the need for pharmacogenomics education among pharmacists in the West Bank of Palestine. Int J Clin Pract 2021;75:e14435. https://doi.org/10.1111/ijcp.14435 .
doi: 10.1111/ijcp.14435
Jarrar, Y, Musleh, R, Hamdan, A, Ghanim, M. Evaluation of the need for pharmacogenomics testing among physicians in the West Bank of Palestine. Drug Metab Pers Ther 2021;36:289–94. https://doi.org/10.1515/dmpt-2021-0121 .
doi: 10.1515/dmpt-2021-0121
Grossniklaus, D. Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing. Test category: pharmacogenomic (treatment). PLoS Curr 2010;2:RRN1155. https://doi.org/10.1371/currents.rrn1155 .
doi: 10.1371/currents.rrn1155
Al-Eitan, LN, Almasri, AY, Khasawneh, RH. Impact of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation therapy. Genes 2018;9:578. https://doi.org/10.3390/genes9120578 .
doi: 10.3390/genes9120578
Ayesh, BM, Abu Shaaban, AS, Abed, AA. Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine. Future Sci OA 2018;4:FSO276. https://doi.org/10.4155/fsoa-2017-0112 .
doi: 10.4155/fsoa-2017-0112
Jarab, AS, Al-Qerem, W, Mukattash, TL, Al-Hajjeh, DM. Pharmacy and Pharm. D students’ knowledge and information needs about COVID-19. Int J Clin Pract 2021;75:e13696. https://doi.org/10.1111/ijcp.13696 .
doi: 10.1111/ijcp.13696
Abubakar, U, Subramaniam, L, Ayinla, A, Ambali, MN, Mohamed Noor, DA, Daud, NAA, et al.. Knowledge, attitude and perception of community pharmacists towards pharmacogenomics services in northern Nigeria: a cross-sectional study. J Pharm Policy Pract 2022;15:39. https://doi.org/10.1186/s40545-022-00435-x .
doi: 10.1186/s40545-022-00435-x
Koufaki, MI, Siamoglou, S, Patrinos, GP, Vasileiou, K. Examining key factors impact on health science students’ intentions to adopt genetic and pharmacogenomics testing: a comparative path analysis in two different healthcare settings. Hum Genom 2022;16:9. https://doi.org/10.1186/s40246-022-00382-3 .
doi: 10.1186/s40246-022-00382-3